Involvement of CCR-2 chemokine receptor activation in ischemic preconditioning and postconditioning of brain in mice

Cytokine

Volumn 60, Issue 1, 2012, Pages 83-89

  Rehni, Ashish K ^a   Singh, Thakur Gurjeet ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

CCR 2 chemokine receptors; Cerebral ischemia; Ischemic postconditioning; Ischemic preconditioning; RS 102895

Indexed keywords

CHEMOKINE RECEPTOR CCR2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; COORDINATION DISORDER; FEMALE; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MALE; MAZE TEST; MEMORY DISORDER; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; ROTAROD TEST; SPATIAL MEMORY;

ANIMALS; BENZOXAZINES; BRAIN; BRAIN ISCHEMIA; CEREBRAL INFARCTION; FEMALE; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; MALE; MAZE LEARNING; MEMORY; MEMORY DISORDERS; MICE; MOTOR ACTIVITY; PIPERIDINES; RECEPTORS, CCR2; REPERFUSION INJURY;

MUS;

EID: 84865410746     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.05.009     Document Type: Article

References (59)

1. Baker K., Markus C.B., Huffman K., Kruk H., Malfory B., Doctrow S.R. Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. J Pharmacol Exp Ther 1998, 284:215-221.
2. Whisnant J.H. The decline of stroke. Stroke 1984, 15:160-168.
3. Murray C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1996, 74:1124-1136.
4. Kitagawa K., Matsumoto M., Tagaya M., Hata R., Ueda H., Niinobe M., et al. 'Ischemic tolerance' phenomenon found in the brain. Brain Res 1990, 528:21-24.
5. Zhao H., Sapolsky R.M., Steinberg G.K. Interrupting reperfusion as a stroke therapy: ischemic postconditioning reduces infarct size after focal ischemia in rats. J Cerebr Blood Flow Metab 2006, 26:1114-1121.
6. Rehni A.K., Singh N. Role of phosphoinositide 3-kinase in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked behavioral deficits in mice. Pharmacol Rep 2007, 59:192-198.
7. Banerjee A., Locke W.C., Rogers K.B., Mitchell M.B., Brew E.C., Cairns C.B., et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 1993, 73:656-670.
8. Yao Z., Gross G.J. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 1993, 264:H2221-H2225.
9. Yao Z., Gross G.J. Role of nitric oxide, muscarinic receptors, and the ATP-sensitive Kq channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res 1993, 73:1193-1201.
10. Goto M., Liu Y., Yang X.M., Ardell J.L., Cohen M.V., Downey J.M. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995, 77:611-621.
11. Liu Y., Tsuchida A., Cohen M.V., Downey J.M. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995, 27:883-892.
12. Mullane K., Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J Mol Cell Cardiol 1995, 27:1041-1054.
13. Erikson J.M., Velasco C.E. Endothelin-1 and myocardial preconditioning. Am Heart J 1996, 132:84-90.
14. Schultz J.E., Hsu A.K., Gross G.J. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996, 78:1100-1104.
15. Lee J.J., Li L., Jung H.H., Zuo Z. Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. Anesthesiology 2008, 108(6):1055-1062.
16. Danielisová V., Némethová M., Gottlieb M., Burda J. The changes in endogenous antioxidant enzyme activity after postconditioning. Cell Mol Neurobiol 2006, 26(7-8):1181-1191.
17. Danielisová V., Gottlieb M., Némethová M., Kravcuková P., Domoráková I., Mechírová E., et al. Bradykinin postconditioning protects pyramidal CA1 neurons against delayed neuronal death in rat hippocampus. Cell Mol Neurobiol 2009, 29:871-878.
18. Zhou Y., Fathali N., Lekic T., Ostrowski R.P., Chen C., Martin R.D., et al. Remote limb ischemic postconditioning protects against neonatal hypoxic-ischemic brain injury in rat pups by the opioid receptor/akt pathway. Stroke 2010, 42:439-444.
19. Cuenca-López M.D., Brea D., Galindo M.F., Antón-Martínez D., Sanz M.J., Agulla J., et al. Inflammatory response during ischaemic processes: adhesion molecules and immunomodulation. Rev Neurol 2010, 51:30-40.
20. Kubo M., Li T.S., Kamota T., Ohshima M., Qin S.L., Hamano K. Increased expression of CXCR4 and integrin alphaM in hypoxia-preconditioned cells contributes to improved cell retention and angiogenic potency. J Cell Physiol 2009, 220:508-514.
21. Mirabelli-Badenier M., Braunersreuther V., Viviani G.L., Dallegri F., Quercioli A., Veneselli E., et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2010, 105:409-420.
22. Tang Y.L., Zhu W., Cheng M., Chen L., Zhang J., Sun T., et al. Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009, 104(10):1209-1216.
23. Shpargel K.B., Jalabi W., Jin Y., Dadabayev A., Penn M.S., Trapp B.D. Preconditioning paradigms and pathways in the brain. Cleve Clin J Med 2008, 75:S77-S81.
24. Voigtsberger S., Lachmann R.A., Leutert A.C., Schläpfer M., Booy C., Reyes L., et al. Sevoflurane ameliorates gas exchange and attenuates lung damage in experimental lipopolysaccharide-induced lung injury. Anesthesiology 2009, 111:1238-1248.
25. Boddeke E.W., Meigel I., Frentzel S., Gourmala N.G., Harrison J.K., Buttini M., et al. Cultured rat microglia express functional beta-chemokine receptors. J Neuroimmunol 1999, 98:176-184.
26. Banisadr G., Gosselin R.D., Mechighel P., Rostene W., Kitabgi P., Melik P.S. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. J Comp Neurol 2005, 492:178-192.
27. Feng X., Yao Y.J. Expression of chemokine receptor CCR2 in cerebral tissue of newborn rat with experimental hypoxic-ischemic brain damage. Sichuan Da Xue Xue Bao Yi Xue Ban 2007, 38:942-964.
28. Mirzadegan T., Diehl F., Ebi B., Bhakta S., Polsky I., McCarley D., et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. J Biol Chem 2000, 275:25562-25571.
29. Onuffer J.J., Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharm Sci 2002, 23:459-467.
30. Ferrara A., Bejaoui S.E., Seyen S., Tirelli E., Plumier J.C. The usefulness of the operant conditioning to assess long-lasting deficits following transient focal ischemia in mice. Behav Brain Res 2009, 205:525-534.
31. Jenkins L.W., Povlishock J.T., Lewelt W., Miller J.D., Becker D.P. The role of postischemic recirculation in the development of ischemic neuronal injury following complete cerebral ischemia. Acta Neuropathol 1981, 5:205-220.
32. Neumar R.W. Molecular mechanisms of ischemic neuronal injury. Ann Emerg Med 2000, 36:483-506.
33. Dobkin B.H. The rehabilitation of elderly stroke patients. Clin Geriatr Med 1991, 7:507-523.
34. Yamamoto Y., Shioda N., Han F., Moriguchi S., Nakajima A., Yokosuka A., et al. Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation. Brain Res 2009, 1295:218-229.
35. Rehni A.K., Bhateja P., Singh N., Jaggi A.S. Implication of mast cell degranulation in ischemic preconditioning-induced prevention of cerebral injury. Fundam Clin Pharmacol 2008, 22:179-188.
36. Rehni A.K., Singh T.G., Jaggi A.S., Singh N. Pharmacological preconditioning of the brain: a possible interplay between opioid and calcitonin gene related peptide transduction systems. Pharmacol Rep 2008, 60:904-913.
37. Rehni A.K., Bhateja P., Singh N. Diethyl dithiocarbamic acid, a possible nuclear factor kappa B inhibitor, attenuates ischemic postconditioning-induced attenuation of cerebral ischemia-reperfusion injury in mice. Can J Physiol Pharmacol 2009, 87:63-68.
38. Rehni A.K., Singh T.G., Bhateja P., Singh N., Arora S. Involvement of cyclic adenosine diphosphoribose receptor activation in ischemic preconditioning induced protection in mouse brain. Brain Res 2010, 1309:75-82.
39. Himori N., Wantanabe H., Akaike N., Kurasawa M., ltoh J., Tanaka Y. Cerebral ischemia model with conscious mice. Involvement of NMDA receptor activation and derangement of learning and memory ability. J Pharmacol Methods. 1990, 23:311-327.
40. Rehni A.K., Shri R., Singh M. Remote ischaemic preconditioning and prevention of cerebral injury. Indian J Exp Biol 2007, 45:247-252.
41. Bochelen D., Rudin M., Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999, 288:653-659.
42. Itoh J., Nabeshima T., Kameyama T. Utility of an elevated plus maze for the evaluation of memory in mice. Effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology 1990, 101:27-32.
43. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
44. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc (Baltimore) 1957, 46:208-209.
45. Matsushima K., Larsen C.G., DuBois G.S., Oppenheim J.J. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989, 169:1485-1490.
46. Allavena P., Bianchi G., Zhou D., Van D.J., Jilek P., Sozzani S., et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994, 24:3233-3236.
47. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemo attractant. Proc Natl Acad Sci USA 1994, 91:3652-3656.
48. McManus C., Berman J.W., Brett F.M., Staunton H., Farrell M., Brosnan C.F. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998, 86:20-29.
49. Conant K., Garzino-Demo A., Nath A., McArthur J.C., Halliday W., Power C., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci USA 1998, 95:3117-3121.
50. Kelder W., McArthur J.C., Nance-Sproson T., McClernon D., Griffin D.E. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998, 44(1998):831-835.
51. Sokolova A., Hill M.D., Rahimi F., Warden L.A., Halliday G.M., Shepherd C.E. Monocyte chemoattractant protein-1 plays a dominantrole in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009, 19:392-398.
52. Wu Y., Wang X., Mo X., Xi Z., Xiao F., Li J., et al. Expression of monocyte chemoattractant protein-1 in brain tissue of patients with intractable epilepsy. Clin Neuropathol 2008, 27(2008):55-63.
53. Alkan T. Neuroproctective effects of ischemic tolerance (preconditioning) and postconditioning. Turk Neurosurg 2009, 19:406-412.
54. Palma-Nicolás J.P., López E., López-Colomé A.M. Thrombin stimulates RPE cell motility by PKC-zeta- and NF-kappaB-dependent gene expression of MCP-1 and CINC-1/GRO chemokines. J Cell Biochem 2010, 110:948-967.
55. Galasso J.M., Miller M.J., Cowell R.M., Harrison J.K., Warren J.S., Silverstein F.S. Acute excitotoxic injury induces expression of monocyte chemoattractant protein-1 and its receptor, CCR2, in neonatal rat brain. Exp Neurol 2000, 165:295-305.
56. Mizutani K., Roca H., Varsos Z., Pienta K.J. Possible mechanism of CCL2-induced Akt activation in prostate cancer cells. Anticancer Res 2009, 29:3109-3113.
57. Yao H., Peng F., Dhillon N., Callen S., Bokhari S., Stehno-Bittel L., et al. Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity. J Neurosci 2009, 29:1657-1669.
58. Webb A., Johnson A., Fortunato M., Platt A., Crabbe T., Christie M.I., et al. Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists. J Leukoc Biol 2008, 84:1202-1212.
59. Quinones M.P., Kalkonde Y., Estrada C.A., Jimenez F., Ramirez R., Mahimainathan L., et al. Role of astrocytes and chemokine systems in acute TNFalpha induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-kappaB and Akt. Mol Cell Neurosci 2008, 37:96-109.